Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy | JACC: Cardiovascular Interventions
PLATO & PEGASUS Efficacy | BRILINTA | For HCPs
Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis | tctmd.com
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI. - ppt video online download
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial | Journal of the American Heart Association
Abstract 16658: Patient Selection for Long-Term Secondary Prevention With Ticagrelor: Insights From PEGASUS-TIMI 54 | Circulation
PEGASUS-TIMI 54: la duplice antiaggregazione con aspirina e ticagrelor a lungo termine riduce gli eventi trombotici ma aumenta le emorragie in pazienti con pregresso infarto miocardico - CardioInfo
PEGASUS-TIMI 54: la duplice antiaggregazione con aspirina e ticagrelor a lungo termine riduce gli eventi trombotici ma aumenta le emorragie in pazienti con pregresso infarto miocardico - CardioInfo
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction | NEJM
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Journal of the American Heart Association
Ticagrelor - Wikipedia
PEGASUS-TIMI 54 – TIMI STUDY GROUP
PEGASUS - Long-term ticagrelor in patients with prior MI — NERDCAT
PDF) Efficacy and Safety with Ticagrelor in Patients with Prior Myocardial Infarction in the Approved European label: Insights from PEGASUS-TIMI 54
PEGASUS-TIMI 45 Trial – Carlsibicky Internal Medicine APPE Blog
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial -
Davide Capodanno on Twitter: "DAPT or DPI in high risk CCS? A few differentiating aspects to aid decisions in patients at low bleeding risk: 1) prior stroke excluded in PEGASUS 2) longer
Davide Capodanno on Twitter: "Notably, the FDA has now approved 4 indications for ticagrelor based on regulatory trials: 1) secondary prevention in ACS (PLATO) 2) secondary prevention in prior MI (PEGASUS) 3)
PLATO & PEGASUS Bleeding | BRILINTA® (ticagrelor) tablets | For HCPs
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI. - ppt download
PEGASUS-TIMI 54 – TIMI STUDY GROUP
Three-year safety and efficacy outcomes of the PEGASUS-TIMI-54 trial. a... | Download Scientific Diagram
PEGASUS TIMI 54 – SIAC
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI. - ppt download
ESC 2017: Subanalysis of PEGASUS shows ticagrelor reduces cardiovascular death by 29% in patients with prior myocardial infarction - Cardiovascular News
Oral antiplatelets and outcomes
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial - ScienceDirect
